These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786 [TBL] [Abstract][Full Text] [Related]
3. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis. Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706 [No Abstract] [Full Text] [Related]
4. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia. Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050 [TBL] [Abstract][Full Text] [Related]
5. Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI. Hui CL; Mautone M Br J Radiol; 2020 Aug; 93(1112):20190989. PubMed ID: 32462892 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma. Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759 [TBL] [Abstract][Full Text] [Related]
7. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Yoneda N; Matsui O; Kitao A; Kozaka K; Kobayashi S; Sasaki M; Yoshida K; Inoue D; Minami T; Gabata T Radiographics; 2016; 36(7):2010-2027. PubMed ID: 27740898 [TBL] [Abstract][Full Text] [Related]
8. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994 [TBL] [Abstract][Full Text] [Related]
9. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions. Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of hypervascular primary hepatic tumors showing hepatobiliary hypointensity on gadoxetic acid-enhanced magnetic resonance imaging. Park HJ; Kim YK; Min JH; Lee J; Lee SJ; Lee ES; Ahn S Abdom Radiol (NY); 2019 Sep; 44(9):3115-3126. PubMed ID: 31134313 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959 [TBL] [Abstract][Full Text] [Related]
13. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging. Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721 [TBL] [Abstract][Full Text] [Related]
14. Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase. Torrisi C; Picone D; Cabibbo G; Matranga D; Midiri M; Brancatelli G Eur J Radiol; 2018 Oct; 107():39-45. PubMed ID: 30292271 [TBL] [Abstract][Full Text] [Related]
15. Current and Advanced Applications of Gadoxetic Acid-enhanced MRI in Hepatobiliary Disorders. Baleato-González S; Vilanova JC; Luna A; Menéndez de Llano R; Laguna-Reyes JP; Machado-Pereira DM; Bermúdez-Naveira A; Osorio-Vázquez I; Alcalá-Mata L; García-Figueiras R Radiographics; 2023 Apr; 43(4):e220087. PubMed ID: 36952256 [TBL] [Abstract][Full Text] [Related]
16. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633 [TBL] [Abstract][Full Text] [Related]
17. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful? Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059 [TBL] [Abstract][Full Text] [Related]
18. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma]. Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944 [TBL] [Abstract][Full Text] [Related]
19. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules. Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242 [TBL] [Abstract][Full Text] [Related]
20. Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI. Chang AI; Kim YK; Min JH; Lee J; Kim H; Lee SJ Abdom Radiol (NY); 2019 Apr; 44(4):1395-1406. PubMed ID: 30515535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]